CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 54 enrolled
Drug / intervention
Lisprodrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02293551
NCT02293551Phase 1Completed
CompareCT.gov

Safety, Tolerability, and Pharmacokinetics of Multiple Novel Insulin Lispro Formulations

Eli Lilly and Company·interventional·Posted Nov 18, 2014·Updated Sep 8, 2025

In Brief

A Phase 1 clinical trial evaluating Lispro for Healthy Volunteers. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The purposes of this study are to determine: * Part A * How quickly your body absorbs, breaks down and gets rid of the different formulations of insulin lispro compared to insulin lispro alone formulation. * The safety of insulin lispro in different formulations and any side effects that might be associated with it. * Part B: * How much insulin lispro from different dose ranges is found in the bloodstream using a test insulin lispro formulation (selected from Part A). * The safety of insulin lispro in different formulations and any side effects that might be associated with it. Participants may only enroll in one part. The study is expected to last up to 10 weeks for each part.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 18, 2014
Enrollment StartDec 1, 2014
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.6 years ago

Interventions

Lisprodrug

Administered SC